CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $160.51M, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
139.09MEUR160.51M · vs all stocks (USD)
Revenue (TTM)
5.81MEUR6.71M · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.3950xvs all stocks
52-Week Change
-18.49%vs all stocks
Market Capitalization
139.09MEUR160.51M · vs all stocks (USD)
Enterprise Value
87.60MEUR101.10M · vs all stocks (USD)
Forward P/E
-4.00xvs Biotechnology peers
Price to Sales (TTM)
23.04xvs Biotechnology peers
Price to Book (MRQ)
1.76xvs Biotechnology peers
Enterprise to Revenue
15.07xvs Biotechnology peers
Enterprise to EBITDA
-2.94xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-399.80%vs Biotechnology peers
Return on Assets (TTM)
-26.12%vs Biotechnology peers
Return on Equity (TTM)
-50.47%vs Biotechnology peers
Revenue (TTM)
5.81MEUR6.71M · vs all stocks (USD)
Revenue per Share (TTM)
0.0190EURUpdated Jul 16, 2026Quarterly Revenue Growth
5.00%vs Biotechnology peers
Gross Profit (TTM)
5.81MEUR6.71M · vs all stocks (USD)
EBITDA (TTM)
-29.79MEUR-34.38M · vs all stocks (USD)
Net Income (TTM)
-29.43MEUR-33.96M · vs all stocks (USD)
Operating Cash Flow (TTM)
-27.28MEUR-31.48M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-17.37MEUR-20.05M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00EURUpdated Jul 16, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00EURFY2025 · Dec 31, 2025Operating Income
-30.75MEUR-35.49M · vs all stocks (USD)
Pre-tax Income
-29.43MEURFY2025 · Dec 31, 2025Income Tax Expense
4.00KEURFY2025 · Dec 31, 2025Net Income
-29.43MEURFY2025 · Dec 31, 2025EBIT
-29.21MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
-28.96MEURFY2025 · Dec 31, 2025Research & Development
28.84MEURFY2025 · Dec 31, 2025Selling, General & Administrative
3.11MEURFY2025 · Dec 31, 2025Other Operating Expenses
-4.44MEURFY2025 · Dec 31, 2025Non-operating Interest Income
1.58MEURFY2025 · Dec 31, 2025Non-operating Interest Expense
211.00KEURFY2025 · Dec 31, 2025EPS (Basic)
-0.1000EURFY2025 · Dec 31, 2025EPS (Diluted)
-0.1000EURFY2025 · Dec 31, 2025Basic Shares Outstanding
300.42MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
300.42MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-29.43MEURFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00EURFY2025 · Dec 31, 2025Operating Cash Flow
-27.87MEURFY2025 · Dec 31, 2025Free Cash Flow
-28.12MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
47.46MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-29.43MEURFY2025 · Dec 31, 2025Stock-based Compensation
1.63MEURFY2025 · Dec 31, 2025Other Non-cash Items
551.00KEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-1.33MEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
713.00KEURFY2025 · Dec 31, 2025Capital Expenditures
-253.00KEURFY2025 · Dec 31, 2025Net Intangibles (CF)
-503.00KEURFY2025 · Dec 31, 2025Other Investing Activity
-1.00KEURFY2025 · Dec 31, 2025Net Investing Cash Flow
-254.00KEURFY2025 · Dec 31, 2025Long-term Debt Payments
-846.00KEURFY2025 · Dec 31, 2025Net Financing Cash Flow
-724.00KEURFY2025 · Dec 31, 2025Shares Outstanding
300.35MSharesUpdated Jul 16, 2026Float Shares
300.41MSharesUpdated Jul 16, 2026% Held by Insiders
34.78%vs all stocks
% Held by Institutions
36.29%vs all stocks
Total Cash (MRQ)
47.46MEUR54.77M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0920EURUpdated Jul 16, 2026Total Debt (MRQ)
1.23MEUR1.42M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0277xvs Biotechnology peers
Current Ratio (MRQ)
4.59xvs Biotechnology peers
Book Value per Share (MRQ)
0.1480EURUpdated Jul 16, 2026Total Assets
57.89MEUR66.81M · vs all stocks (USD)
Total Current Assets
54.89MEURFY2025 · Dec 31, 2025Total Liabilities
13.41MEURFY2025 · Dec 31, 2025Total Non-current Assets
3.00MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
1.44MEURFY2025 · Dec 31, 2025Total Current Liabilities
11.97MEURFY2025 · Dec 31, 2025Cash
20.67MEURFY2025 · Dec 31, 2025Cash Equivalents
26.79MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
47.46MEURFY2025 · Dec 31, 2025Accounts Payable
5.56MEURFY2025 · Dec 31, 2025Short-term Debt
1.16MEURFY2025 · Dec 31, 2025Long-term Debt
124.00KEURFY2025 · Dec 31, 2025Other Non-current Liabilities
1.01MEURFY2025 · Dec 31, 2025Common Stock (Book)
30.07MEURFY2025 · Dec 31, 2025Retained Earnings
-64.59MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
44.48MEUR51.33M · vs all stocks (USD)
Treasury Stock
119.00KEURFY2025 · Dec 31, 202552-Week Low
0.2220EURUpdated Jul 16, 202652-Week High
0.8080EURUpdated Jul 16, 202652-Week Change
-18.49%vs all stocks
Beta
0.3950xvs all stocks
50-Day MA
0.3302EURUpdated Jul 16, 2026200-Day MA
0.3555EURUpdated Jul 16, 2026Avg 10-Day Volume
711.01KSharesUpdated Jul 16, 2026Avg 30-Day Volume
1.66MSharesUpdated Jul 16, 2026Diluted EPS (TTM)
-0.1000EURUpdated Jul 16, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 23.04Revenue Growth YoY: 0.05
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.56
Altman Z-Score 3.89: safe zoneNotable
Altman Z-Score: 3.89
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $160.51M, lower than 95% of all stocks globallySignificant
Market cap (USD): 160,513,990.773Global P5: 269,387,740.27
Revenue is $6.71M, lower than 95% of all stocks globallySignificant
Revenue (USD): 6,709,704.84Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Mycenax Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Graphy Inc.
Tier 1ProductionApproval-Gated PipelineRule
Journey Medical Corp
Tier 1ProductionApproval-Gated PipelineRule
Alector Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chill Brands Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
S Biomedics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Asterasys Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
EKF Diagnostics Holdings plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
HLB Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Yungjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Guangdong Guangzhou Daily Media Co., Ltd.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Everspin Technologies Inc.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
CETC Chips Technology Inc.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity